Dr. Scott Moonly is experienced in all aspects of life sciences with a truly broad experience spanning academic research, consulting, investment banking, Venture Capital and start-up management.
Dr. Moonly is a former investment banker at Merrill Lynch where he was an analyst on the largest Biotech Merger at that time – Amgen’s purchase of Immunex. Additionally, he completed a follow on offering for biotech, and analyzed multiple M&A deals in the medical technology space.
Scott was also a strategy consultant with L.E.K. Consulting where he developed the Oncology strategy for a large Biotech company. Additionally, he helped to develop the healthcare royalty securitization industry as lead consultant on multiple landmark deals in the space. Additionally, he provided guidance on the largest generic drug merger at the time.
Dr. Moonly also has experience as a Venture Capitalist with Johnson & Johnson Development Corporation (JJDC), the Venture Capital arm of Johnson and Johnson. While there he completed many investments in the medical technology, digital health and Venture Capital fund space. He led the relationships with Ethicon Endosurgery, and Cordis, helping each organization develop their investing and corporate strategies. Additionally, developed white space investing strategies for the Venture Capital group, most notably their digital health strategy.
President and CEO of USGI Medical. Increased sales ~300% over 3 years, developed finalized procedure for weight loss, and led the execution of multiple landmark studies including a U.S. pivotal trial. During this time period, Scott raised ~$50M in equity and debt for the company including a large investment by Johnson and Johnson to fund the US pivotal trial.
Dr. Moonly holds a Bachelors of Science in Bioengineering from University of California (San Diego, 1993-1998) and a PhD in Bioengineering from University of California, Berkeley/ University of California, San Francisco (1998-2003).